RT Journal Article
SR Electronic
T1 Generalizing AI-driven Assessment of Immunohistochemistry across Immunostains and Cancer Types: A Universal Immunohistochemistry Analyzer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.16.24310406
DO 10.1101/2024.07.16.24310406
A1 Brattoli, Biagio
A1 Mostafavi, Mohammad
A1 Lee, Taebum
A1 Jung, Wonkyung
A1 Ryu, Jeongun
A1 Park, Seonwook
A1 Park, Jongchan
A1 Pereira, Sergio
A1 Shin, Seunghwan
A1 Choi, Sangjoon
A1 Kim, Hyojin
A1 Yoo, Donggeun
A1 Ali, Siraj M.
A1 Paeng, Kyunghyun
A1 Ock, Chan-Young
A1 Cho, Soo Ick
A1 Kim, Seokhwi
YR 2024
UL http://medrxiv.org/content/early/2024/07/16/2024.07.16.24310406.abstract
AB Despite advancements in methodologies, immunohistochemistry (IHC) remains the most utilized ancillary test for histopathologic and companion diagnostics in targeted therapies. However, objective IHC assessment poses challenges. Artificial intelligence (AI) has emerged as a potential solution, yet its development requires extensive training for each cancer and IHC type, limiting versatility. We developed a Universal IHC (UIHC) analyzer, an AI model for interpreting IHC images regardless of tumor or IHC types, using training datasets from various cancers stained for PD-L1 and/or HER2. This multi-cohort trained model outperforms conventional single-cohort models in interpreting unseen IHCs (Kappa score 0.578 vs. up to 0.509) and consistently shows superior performance across different positive staining cutoff values. Qualitative analysis reveals that UIHC effectively clusters patches based on expression levels. The UIHC model also quantitatively assesses c-MET expression with MET mutations, representing a significant advancement in AI application in the era of personalized medicine and accumulating novel biomarkers.Competing Interest StatementBiagio Brattoli, Mohammad Mostafavi, Taebum Lee, Jeongun Ryu, Seonwook Park, Jongchan Park, Sergio Pereira, Seunghwan Shin, Donggeun Yoo, Siraj M. Ali, Kyunghyun Paeng, Chan-Young Ock, and Soo Ick Cho are employees of Lunit and/or have stock/stock options in Lunit.Funding StatementThis work was supported by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science and ICT (MSIT) (2022R1C1C1007289), Republic of Korea, new faculty research fund of Ajou University School of Medicine, and Lunit.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data for this study were obtained from commercially available sources from Cureline Inc. (Brisbane, CA, US), Aurora Diagnostics (Greensboro, NC, US), Neogenomics (Fort Myers, FL, US), Superbiochips (Seoul, Republic of Korea) or were available by the permission of Institutional Review Board (IRB) from Samsung Medical Center (IRB no. 2018-06-103), Seoul National University Bundang Hospital (IRB no. B-2101/660-30), and Ajou University Medical Center (IRB no. AJOUIRB-KS-2023-425). All slide images and clinical information were de-identified and pseudonymized.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes